Histopathologic Effect of Calcium Electroporation on Cancer in the Skin (CAEP-B)

• ClinicalTrials.gov Identifier: NCT04259658
• Recruitment Status: Recruiting
• First Posted: February 6, 2020
• Last Update Posted: December 13, 2022
• Sponsor: Zealand University Hospital
• Information provided by (Responsible Party): Zealand University Hospital

Study Description

Brief Summary:

In this phase II study we investigate the effect of calcium electroporation on cancer in the skin investigated by histopathology.

Condition or disease	Intervention/treatment	Phase
Cancer	Combination Product: Calcium electroporation	Phase 2

Detailed Description:

In this non randomized phase II study, we will explore histopathological tumour cell death mechanisms in 24 patients with breast cancer metastases or other cutaneous or subcutaneous malignancy. The primary endpoint of the biopsy study is to evaluate differences in tumour infiltrating lymphocyte (TIL) population in tissue samples from treated cancer tumours two days after calcium electroporation treatment compared to samples taken on the day of treatment before the calcium electroporation procedure. TIL content in biopsies will be evaluated by pathological examination and specified in percent of cells. Patients will be followed up to 3 months and depending on number of treated tumors, biopsies will be taken at different timepoints after one or two treatments with calcium electroporation. Other analyses will include differences regarding tumour type, immune marker expression levels over time, vascular effects and regressive changes as well as examining changes in systemic immunological markers.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 24 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment

Intervention Model Description

Prospective phase II clinical study: Patients with cutaneous metastases will be recruited at the Department of Oncology, Zealand University Hospital (ZUH). One cohort of 24 patients with respectively disseminated breast cancer or other solid tumour malignancies, will be included. This will be a non-randomized trial.

All patients will have been offered the standard of care and all available alternatives before entering the protocol. Calcium electroporation will not be compared to other means of treatment.

All patients will be treated once and patients with over 3 metastases will be offered retreatment of some of their metastases. A maximum of 2 treatments per patient will be conducted with an interval of minimum 4 weeks. The patients will be followed with regular examinations for 3 months, starting from first treatment day.

• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Investigation of the Histopathologic Effect of Calcium Electroporation on Cancer in the Skin (CAEP-B)
• Actual Study Start Date: April 20, 2020
• Estimated Primary Completion Date: August 1, 2023
• Estimated Study Completion Date: February 1, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Calcium electroporation treatment; Experimental treatment with calcium electroporation for cutaneous metastases.	Combination Product: Calcium electroporation; Patients with cutaneous metastases will be treated with calcium electroporation.

Outcome Measures

Primary Outcome Measures :

1. The effect of calcium electroporation on tumor infiltrating lymphocyte (TIL) population. [ Time Frame: 2 days ]
   The primary endpoint of this study is to evaluate differences in TIL population in tissue samples from treated cancer tumours two days after calcium electroporation treatment compared to before treatment (biopsy taken on the day of treatment before the calcium electroporation procedure). TIL content in biopsies will be evaluated by pathological examination and expressed as percent of cells.

Secondary Outcome Measures :

1. Changes in immune markers [ Time Frame: 3 months ]
   Protein expression levels of immune markers e.g. markers for the innate and adaptive immune system and markers of the STING pathway compared from before treatment and at different timepoints up to 3 months.
2. Tumour inflammation signature (TIS) [ Time Frame: 3 months ]
   Gene expression signatures including the 18-gene TIS will be calculated as a weighted linear average of the constituent genes.
3. Molecular subtype classification [ Time Frame: 3 months ]
   Gene expression profiling according to tumour histology.
4. Size of lesion [ Time Frame: 3 months ]
   To clinically measure changes in lesion size 1, 2 and 3 months after treatment using caliper measurement. Changes in size due to biopsies will be accounted for.
5. TIL population and tumour type [ Time Frame: 3 months ]
   To describe any relation between change in TIL population (percentage of cells) and tumour type before and after calcium electroporation.
6. Tumour regression [ Time Frame: 3 months ]
   To describe presence of regressive changes including necrosis at different timepoints (percentage of tissue).
7. Residual tumour [ Time Frame: 3 months ]
   To describe presence of residual tumour (yes/no) and description of topographical location.
8. Vascular effects [ Time Frame: 3 months ]
   To investigate vascular effects of calcium electroporation including changes in capillary structures by histochemical staining for endothelial biomarkers CD31 and/or CD34.
9. Clinical response to intervention [ Time Frame: 3 months ]
   To document evolution of tumours before and after treatment using digital photography including a ruler.
10. Complete response at patient level [ Time Frame: 3 months ]
    To sum number of patients with complete response after one or two treatments, respectively. Complete response will be defined as disappearance of all target lesions.
11. Complete disappearance of treated lesions (in relation to all lesions treated) [ Time Frame: 3 months ]
    To sum number of lesions across all patients with complete remission after one or two treatments, respectively (expressed at percentage of all treated lesions).
12. Tumour type [ Time Frame: 3 months ]
    To establish number of treated tumours with complete response depending on tumour type.
13. Systemic immunologic response [ Time Frame: 3 months ]
    To detect signs of systemic immunologic response from any routine scans before and after treatment in the inclusion period.
14. Importance of previous irradiation [ Time Frame: 3 months ]
    To investigate differences in effect depending whether the treated tumour was in a previously irradiated area.
15. Adjacent non-tumour tissue [ Time Frame: 3 months ]
    To evaluate effect on adjacent non-tumour tissue.
16. PD-L1 expression over time [ Time Frame: 3 months ]
    To assess PD-L1 expression over time by biopsy.
17. Relation between change in PD-L1 expression and response [ Time Frame: 3 months ]
    To investigate any relation between change in PD-L1 expression and tumour response.
18. PD-L1 expression in relation to cell types [ Time Frame: 3 months ]
    To describe PD-L1 expression in relation to cell types found in the tumour environment
19. PD-L1 expression of different tumour histologies [ Time Frame: 3 months ]
    To describe PD-L1 expression on different cell types of the different tumour histologies investigated.
20. Western blotting [ Time Frame: 3 months ]
    To examine frozen tissues samples by western blotting in order to support any of the above mentioned endpoints.
21. Systemic immune factors after calcium electroporation [ Time Frame: 3 months ]
    Blood samples may be analyzed for NK cell- and T-cell gene expression levels. Levels before and after treatment will be compared.
22. Current measurement [ Time Frame: 1 month ]
    To measure current during treatment as indicated by the pulse generator.
23. PCR [ Time Frame: 3 months ]
    To examine frozen tissues samples by PCR. Relevant gene expression will be compared before and after treatment in breast cancer and non breast cancer samples.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Trial subject must be able to understand the participant information.
• Histologically verified cutaneous or subcutaneous, primary or secondary cancer of any histology.
• The patient can undergo any simultaneous medical treatment (endocrine therapy, chemotherapy, immunotherapy etc.).
• The patient can undergo radiation therapy during the study period, provided that the treatment field does not involve the treated area.
• Performance status ECOG/WHO ≤2
• At least one cutaneous or subcutaneous tumour measuring at least 5 mm.
• Both men and women who are sexually active must use safe contraception (contraceptive coil, deposit injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch.)
• Signed informed consent.

Exclusion Criteria:

• Pregnancy or lactation
• Allergy to local anaesthesia

Contacts and Locations

Contacts

Contact: Mille Vissing, MD; 0045 42674199; emlh@regionsjaelland.dk

Contact: Julie Gehl, MD; kgeh@regionsjaelland.dk

Locations

Denmark

Dept. of Clinical oncology and Palliative Care; Recruiting

Næstved, Denmark

Contact: Julie Gehl, Professor

Sponsors and Collaborators

Zealand University Hospital

Investigators

• Principal Investigator: Julie Gehl, MD; Zealand University Hospital

More Information

• Responsible Party: Zealand University Hospital
• ClinicalTrials.gov Identifier: NCT04259658
• Other Study ID Numbers: REG-114-2019
• First Posted: February 6, 2020
• Last Update Posted: December 13, 2022
• Last Verified: December 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Zealand University Hospital:

calcium; electroporation; tumor infiltrating lymphocytes; cancer; metastases

Additional relevant MeSH terms:

Calcium; Calcium-Regulating Hormones and Agents; Physiological Effects of Drugs